Table 4.
Results of subgroup analysis of pooled hazard ratios of PFS of patients
| Stratified analysis | No. of studies | Pooled HR (95% CI) | P‐value | Heterogeneity | |
|---|---|---|---|---|---|
| I2 (%) | PQ | ||||
| Cancer type | |||||
| RCC | 4 | 1.52 (0.99, 2.31) | 0.050 | 91 | < 0.001 |
| PC | 1 | 11.8 (5.6, 24.87) | < 0.001 | NA | NA |
| Unclear | 2 | 1.6 (1.23, 2.07) | < 0.001 | 0 | 0.900 |
| Urothelial cancer | 2 | 1.6 (1.23, 2.07) | < 0.001 | 0 | 0.900 |
| Non urothelial cancer | 5 | 2.31 (1.23, 3.69) | 0.007 | 95 | < 0.001 |
| Treatment | |||||
| Surgery | 2 | 1.16 (0.8, 1.7) | 0.430 | 62 | 0.110 |
| Non surgery | 4 | 2.65 (1.53, 4.58) | < 0.001 | 88 | < 0.001 |
| Mix | 1 | 1.43 (0.89, 2.3) | 0.140 | NA | NA |
| Study type | |||||
| Prospective | 1 | 1.43 (0.89, 2.3) | 0.140 | NA | NA |
| Retrospective | 6 | 2.03 (1.29, 3.2) | 0.002 | 94 | < 0.001 |
| Analysis | |||||
| Multivariate | 5 | 1.93 (1.14, 3.29) | 0.010 | 93 | < 0.001 |
| Univariate | 2 | 1.91 (1.53, 2.38) | < 0.001 | 0 | 0.550 |
CI: confidence interval; HR: hazard ratio; OS: overall survival; SII: systemic immune‐inflammation index